Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.

Bocchia M, Candoni A, Borlenghi E, Defina M, Filì C, Cattaneo C, Sammartano V, Fanin R, Sciumè M, Sicuranza A, Imbergamo S, Riva M, Fracchiolla N, Latagliata R, Caizzi E, Mazziotta F, Alunni G, Di Bona E, Crugnola M, Rossi M, Consoli U, Fontanelli G, Greco G, Nadali G, Rotondo F, Todisco E, Bigazzi C, Capochiani E, Molteni A, Bernardi M, Fumagalli M, Rondoni M, Scappini B, Ermacora A, Simonetti F, Gottardi M, Lambertenghi Deliliers D, Michieli M, Basilico C, Galeone C, Pelucchi C, Rossi G.

Hematol Oncol. 2019 Oct;37(4):447-455. doi: 10.1002/hon.2663. Epub 2019 Aug 20.

PMID:
31385337
2.

Correction: Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis.

Cassano M, Biressi S, Finan A, Benedetti L, Omes C, Boratto R, Martin F, Allegretti M, Broccoli V, Cusella De Angelis G, Comoglio PM, Basilico C, Torrente Y, Michieli P, Cossu G, Sampaolesi M.

PLoS One. 2019 Jul 24;14(7):e0220357. doi: 10.1371/journal.pone.0220357. eCollection 2019.

3.

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk.

Modica C, Tortarolo D, Comoglio PM, Basilico C, Vigna E.

Int J Mol Sci. 2018 Dec 7;19(12). pii: E3920. doi: 10.3390/ijms19123920. Review.

4.

Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma.

Maurizi G, Verma N, Gadi A, Mansukhani A, Basilico C.

Oncogene. 2018 Aug;37(33):4626-4632. doi: 10.1038/s41388-018-0292-2. Epub 2018 May 10.

5.

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.

Basilico C, Modica C, Maione F, Vigna E, Comoglio PM.

Int J Cancer. 2018 Oct 1;143(7):1774-1785. doi: 10.1002/ijc.31550. Epub 2018 May 10. Erratum in: Int J Cancer. 2019 May 15;144(10):E5.

6.

Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).

Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Todisco E, Fracchiolla N, Mancini V, Turrini M, Da Vià M, Sala E, Cattaneo C, Petullà M, Serana F, Ferrario A, Cairoli R, Cortelezzi A, Santoro A, Castagnola C, Rossi G.

Am J Hematol. 2018 Feb;93(2):E54-E57. doi: 10.1002/ajh.24977. Epub 2017 Dec 4. No abstract available.

7.

Myeloid Zinc Finger 1 and GA Binding Protein Co-Operate with Sox2 in Regulating the Expression of Yes-Associated Protein 1 in Cancer Cells.

Verma NK, Gadi A, Maurizi G, Roy UB, Mansukhani A, Basilico C.

Stem Cells. 2017 Dec;35(12):2340-2350. doi: 10.1002/stem.2705. Epub 2017 Sep 29.

8.

Phosphoproteomics of Fibroblast Growth Factor 1 (FGF1) Signaling in Chondrocytes: Identifying the Signature of Inhibitory Response.

Chapman JR, Katsara O, Ruoff R, Morgenstern D, Nayak S, Basilico C, Ueberheide B, Kolupaeva V.

Mol Cell Proteomics. 2017 Jun;16(6):1126-1137. doi: 10.1074/mcp.M116.064980. Epub 2017 Mar 15.

9.

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F.

Expert Opin Investig Drugs. 2017 Mar;26(3):367-373. doi: 10.1080/13543784.2017.1288213. Epub 2017 Feb 9. Review.

PMID:
28140696
10.

A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion.

Pessina C, Basilico C, Genoni A, Meroni E, Elli L, Granata P, Righi R, Pallotti F, Mora B, Ferrario A, Passamonti F, Casalone R.

Leuk Lymphoma. 2017 Aug;58(8):1977-1980. doi: 10.1080/10428194.2016.1262952. Epub 2016 Dec 2. No abstract available.

PMID:
27911132
11.

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.

Godar M, Morello V, Sadi A, Hultberg A, De Jonge N, Basilico C, Hanssens V, Saunders M, Lambrecht BN, El Khattabi M, de Haard H, Michieli P, Blanchetot C.

Sci Rep. 2016 Aug 22;6:31621. doi: 10.1038/srep31621.

12.

PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.

Basu-Roy U, Han E, Rattanakorn K, Gadi A, Verma N, Maurizi G, Gunaratne PH, Coarfa C, Kennedy OD, Garabedian MJ, Basilico C, Mansukhani A.

Oncotarget. 2016 Sep 20;7(38):60954-60970. doi: 10.18632/oncotarget.11273.

13.

Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.

Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F, Comoglio PM.

Mol Oncol. 2015 Nov;9(9):1760-72. doi: 10.1016/j.molonc.2015.05.007. Epub 2015 Jun 5.

14.

Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C.

Nat Commun. 2015 Apr 2;6:6411. doi: 10.1038/ncomms7411.

15.

Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.

Prat M, Oltolina F, Basilico C.

Biomedicines. 2014 Dec 3;2(4):359-383. doi: 10.3390/biomedicines2040359. Review.

16.

Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy.

Gastaldi M, Ferrario A, Basilico C, Merli M, Mauri M, Tibiletti MG, Passamonti F, Franciotta D, Bono G.

J Neurol Sci. 2014 Sep 15;344(1-2):234-5. doi: 10.1016/j.jns.2014.06.036. Epub 2014 Jun 24. No abstract available.

PMID:
24996491
17.

PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization.

Rossi G, Skert C, Morello E, Almici C, Arcaini L, Basilico C, Cavalli L, Botto B, Castelli A, Pica G, Ripamonti F, Salvi F, Carella AM, Gaidano G, Levis A, Nosari A, Russo D, Vitolo U.

Hematol Oncol. 2015 Sep;33(3):125-32. doi: 10.1002/hon.2148. Epub 2014 May 29.

PMID:
24890497
18.

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P.

J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27.

19.

FIREWACh: high-throughput functional detection of transcriptional regulatory modules in mammalian cells.

Murtha M, Tokcaer-Keskin Z, Tang Z, Strino F, Chen X, Wang Y, Xi X, Basilico C, Brown S, Bonneau R, Kluger Y, Dailey L.

Nat Methods. 2014 May;11(5):559-65. doi: 10.1038/nmeth.2885. Epub 2014 Mar 23.

20.

Morphological comparison of the craniofacial phenotypes of mouse models expressing the Apert FGFR2 S252W mutation in neural crest- or mesoderm-derived tissues.

Heuzé Y, Singh N, Basilico C, Jabs EW, Holmes G, Richtsmeier JT.

Bone. 2014 Jun;63:101-9. doi: 10.1016/j.bone.2014.03.003. Epub 2014 Mar 13.

21.

SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage.

Seo E, Basu-Roy U, Gunaratne PH, Coarfa C, Lim DS, Basilico C, Mansukhani A.

Cell Rep. 2013 Jun 27;3(6):2075-87. doi: 10.1016/j.celrep.2013.05.029. Epub 2013 Jun 20.

22.

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.

Michieli P, Basilico C, Pennacchietti S.

Clin Cancer Res. 2013 Aug 1;19(15):4291. doi: 10.1158/1078-0432.CCR-13-1534. Epub 2013 Jun 13. No abstract available.

23.

The B55α regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes.

Kolupaeva V, Daempfling L, Basilico C.

Mol Cell Biol. 2013 Aug;33(15):2865-78. doi: 10.1128/MCB.01730-12. Epub 2013 May 28.

24.

Novel agents in indolent lymphomas.

Merli M, Ferrario A, Basilico C, Maffioli M, Caramazza D, Appio L, Arcaini L, Passamonti F.

Ther Adv Hematol. 2013 Apr;4(2):133-48. doi: 10.1177/2040620712466865.

25.

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P.

Clin Cancer Res. 2013 May 1;19(9):2381-92. doi: 10.1158/1078-0432.CCR-12-3459. Epub 2013 Mar 26.

26.

Isolation and analysis of DNA derived from nucleosome-free regions.

Murtha M, Wang Y, Basilico C, Dailey L.

Methods Mol Biol. 2013;977:35-51. doi: 10.1007/978-1-62703-284-1_4.

PMID:
23436352
27.

Overexpression of cyclin E/CDK2 complexes overcomes FGF-induced cell cycle arrest in the presence of hypophosphorylated Rb proteins.

Kolupaeva V, Basilico C.

Cell Cycle. 2012 Jul 1;11(13):2557-66. doi: 10.4161/cc.20944. Epub 2012 Jul 1.

28.

Mesodermal expression of Fgfr2S252W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome.

Holmes G, Basilico C.

Dev Biol. 2012 Aug 15;368(2):283-93. doi: 10.1016/j.ydbio.2012.05.026. Epub 2012 Jun 1.

29.

Perspectives on cancer stem cells in osteosarcoma.

Basu-Roy U, Basilico C, Mansukhani A.

Cancer Lett. 2013 Sep 10;338(1):158-67. doi: 10.1016/j.canlet.2012.05.028. Epub 2012 May 29. Review.

30.

Regulation of cranial morphogenesis and cell fate at the neural crest-mesoderm boundary by engrailed 1.

Deckelbaum RA, Holmes G, Zhao Z, Tong C, Basilico C, Loomis CA.

Development. 2012 Apr;139(7):1346-58. doi: 10.1242/dev.076729.

31.

Distinct functions of Sox2 control self-renewal and differentiation in the osteoblast lineage.

Seo E, Basu-Roy U, Zavadil J, Basilico C, Mansukhani A.

Mol Cell Biol. 2011 Nov;31(22):4593-608. doi: 10.1128/MCB.05798-11. Epub 2011 Sep 19.

32.

Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas.

Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A, Basilico C.

Oncogene. 2012 May 3;31(18):2270-82. doi: 10.1038/onc.2011.405. Epub 2011 Sep 19.

33.

The Sox2 high mobility group transcription factor inhibits mature osteoblast function in transgenic mice.

Holmes G, Bromage TG, Basilico C.

Bone. 2011 Oct;49(4):653-61. doi: 10.1016/j.bone.2011.06.008. Epub 2011 Jun 15.

34.

Regulation of non-classical FGF1 release and FGF-dependent cell transformation by CBF1-mediated notch signaling.

Kacer D, McIntire C, Kirov A, Kany E, Roth J, Liaw L, Small D, Friesel R, Basilico C, Tarantini F, Verdi J, Prudovsky I.

J Cell Physiol. 2011 Nov;226(11):3064-75. doi: 10.1002/jcp.22663. Erratum in: J Cell Physiol. 2012 Jul;227(7):2973.

35.

FGF inhibits the activity of the cyclin B1/CDK1 kinase to induce a transient G₂arrest in RCS chondrocytes.

Tran T, Kolupaeva V, Basilico C.

Cell Cycle. 2010 Nov 1;9(21):4379-86. Epub 2010 Nov 15.

36.

The transcription factor Sox2 is required for osteoblast self-renewal.

Basu-Roy U, Ambrosetti D, Favaro R, Nicolis SK, Mansukhani A, Basilico C.

Cell Death Differ. 2010 Aug;17(8):1345-53. doi: 10.1038/cdd.2010.57. Epub 2010 May 21.

37.

Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology.

Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, Basilico C.

Dev Biol. 2009 Apr 15;328(2):273-84. doi: 10.1016/j.ydbio.2009.01.026. Epub 2009 Jan 29.

38.

"Active" cancer immunotherapy by anti-Met antibody gene transfer.

Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C, Pennacchietti S, Comoglio PM.

Cancer Res. 2008 Nov 15;68(22):9176-83. doi: 10.1158/0008-5472.CAN-08-1688.

39.

PP2A-mediated dephosphorylation of p107 plays a critical role in chondrocyte cell cycle arrest by FGF.

Kolupaeva V, Laplantine E, Basilico C.

PLoS One. 2008;3(10):e3447. doi: 10.1371/journal.pone.0003447. Epub 2008 Oct 17.

40.

Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis.

Cassano M, Biressi S, Finan A, Benedetti L, Omes C, Boratto R, Martin F, Allegretti M, Broccoli V, Cusella De Angelis G, Comoglio PM, Basilico C, Torrente Y, Michieli P, Cossu G, Sampaolesi M.

PLoS One. 2008 Sep 16;3(9):e3223. doi: 10.1371/journal.pone.0003223. Erratum in: PLoS One. 2019 Jul 24;14(7):e0220357.

41.

Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transcription in osteoblasts.

Ambrosetti D, Holmes G, Mansukhani A, Basilico C.

Mol Cell Biol. 2008 Aug;28(15):4759-71. doi: 10.1128/MCB.01849-07. Epub 2008 May 27.

42.

A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.

Basilico C, Arnesano A, Galluzzo M, Comoglio PM, Michieli P.

J Biol Chem. 2008 Jul 25;283(30):21267-77. doi: 10.1074/jbc.M800727200. Epub 2008 May 21.

43.

Identification of active transcriptional regulatory modules by the functional assay of DNA from nucleosome-free regions.

Yaragatti M, Basilico C, Dailey L.

Genome Res. 2008 Jun;18(6):930-8. doi: 10.1101/gr.073460.107. Epub 2008 Apr 25.

44.

Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways.

Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A.

J Cell Physiol. 2008 May;215(2):442-51.

PMID:
17960591
45.

Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients.

Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, Grossi P.

Transplantation. 2007 Sep 27;84(6):685-8.

PMID:
17893600
46.

Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes.

Priore R, Dailey L, Basilico C.

J Cell Physiol. 2006 Jun;207(3):800-8.

PMID:
16523491
47.

A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control.

Budagian V, Bulanova E, Orinska Z, Thon L, Mamat U, Bellosta P, Basilico C, Adam D, Paus R, Bulfone-Paus S.

EMBO J. 2005 Dec 21;24(24):4260-70. Epub 2005 Nov 24. Retraction in: EMBO J. 2011 Feb 2;30(3):627.

48.

Fatal lactic acidosis associated with tenofovir and abacavir.

Giola M, Basilico C, Grossi P.

Int J Infect Dis. 2005 Jul;9(4):228-9. No abstract available.

49.

Mechanisms underlying differential responses to FGF signaling.

Dailey L, Ambrosetti D, Mansukhani A, Basilico C.

Cytokine Growth Factor Rev. 2005 Apr;16(2):233-47. Epub 2005 Mar 5. Review.

PMID:
15863038
50.

Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation.

Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C.

J Cell Biol. 2005 Mar 28;168(7):1065-76. Epub 2005 Mar 21.

Supplemental Content

Loading ...
Support Center